PIONEER Trial Begins Enrollment for Balt’s Silk Vista Baby Flow Diverter

October 5, 2026—Balt announced that the first patients in North America have been enrolled in its premarket approval clinical trial, PIONEER, a pivotal study evaluating the company’s Silk Vista Baby flow diverter for the treatment of unruptured intracranial aneurysms. The trial is being conducted to support approval for the device in the United States.

According to the company, the prospective PIONEER trial focuses exclusively on the role of flow diversion to treat aneurysms in small distal arteries in the brain. Enrollment is underway at hospitals in both the United States and Canada.

Balt stated that the Silk Vista Baby flow diverter device can be delivered through a 0.017-inch-diameter microcatheter. The device received European CE Mark approval in 2018.

The PIONEER trial's Coprimary Investigators are Vitor Mendes-Pereira, MD, with St. Michael’s Hospital in Toronto, Canada, and Ricardo Hanel, MD, with Baptist Medical Center in Jacksonville, Florida.

“The Silk Vista Baby has been a paradigm shift in the care of neurovascular patients,” commented Dr. Mendes-Pereira in the company’s press release. “It provides physicians with a significant improvement on access to distal aneurysms with a low-profile microcatheter over the treatment options we have available and enables us to provide better care for more patients.”

“The PIONEER study is an important advance for the care of aneurysm patients in the United States.," added Dr. Hanel. "This study will add tremendously to our knowledge of how to care for patients with distal aneurysms and potentially brings another life-saving tool to the patients of the United States.”